INTRODUCTION {#s1}
============

Prostate cancer (PCa) is second-most commonly diagnosed malignancy in males, and thought to be one of the leading causes of cancer-related death around the world. In 2014, approximately 233,000 newly diagnosed cases and 30,000 PCa-related deaths was reported in America \[[@R1]\]. Furthermore, the global incidence is rising rapidly. By 2030, the number of new PCa and PCa-related deaths annually will climb to 1,853,391 and 544,209, respectively \[[@R2]\]. The etiology of PCa has remained unclear. Several factors are considered to significant increase the risk of PCa, including ethnicity, hormonal status, environment, diet, aging, and genetic factors \[[@R3]\].

Low serum levels of vitamin D might be one of the risk factors for PCa \[[@R4]\]. Laboratory investigation demonstrated that vitamin D inhibits the growth and differentiation of PCa cells, decreases the invasion, metabolism and angiogenesis of tumor cell. It can also promote tumor cell apoptosis \[[@R4]\]. In 2007, a clinical trial suggested that calcitriol, a kind of analogue of vitamin D can significantly improve patients' survival rate by decreasing serum level of prostate special antigen (PSA) \[[@R5]\]. The antineoplastic effect of vitamin D is activated when binding to vitamin D receptor (*VDR*) \[[@R6]\]. 1,25-Dihydroxy vitamin D3(1,25(OH)~2~D~3~) is the hormonally active form of vitamin D. It binds to *VDR* and forms a heterodimer complex, which subsequently binds to the vitamin D response element and reduces the transcription levels of many genes that stimulating the cell growth and differentiation \[[@R7], [@R8]\].

Recently, the relationship of several single nucleotide polymorphisms (SNPs) of *VDR* gene and PCa risk has been the focus of research attention \[[@R8], [@R9]\]. *Taq I* polymorphism (rs731236) is one of the most widely-studied SNPs. It is a synonymous mutation located in exon 9 of *VDR* gene \[[@R10]\]. This mutation could reduce the mRNA stability and therefore decrease the mRNA levels of *VDR* gene \[[@R11]\]. Recently, some studies have suggested that *Taq I* variation might increase the susceptibility of PCa \[[@R12], [@R13]\]. However, these results are debatable and inconsistent in the effect of *Taq I* polymorphism on PCa risk. Numerous studies in favor of the association of *Taq I* polymorphisms and PCa risk \[[@R14]--[@R19]\]. Meanwhile, some studies disapprove of the relationship \[[@R20]--[@R22]\]. The difference might be due to under-power for individual study. Moreover, previous meta-analyses \[[@R10], [@R23], [@R24]\] seem to be outdated since new data appeared \[[@R17], [@R25]--[@R27]\]. Therefore, we conduct this meta-analysis to get more accurate results.

RESULTS {#s2}
=======

Characteristics of studies {#s2_1}
--------------------------

We identified 288 potentially relevant studies following the retrieval strategy. Based on the inclusion criteria, 36 studies \[[@R3], [@R7], [@R9], [@R12], [@R14]--[@R19], [@R22], [@R25]--[@R49]\] between 1996 to 2017 were finally included (Figure [1](#F1){ref-type="fig"}). The number of cases and controls varied from 28 to 1,617, and 41 to 1,072, respectively (Table [1](#T1){ref-type="table"}). The genotype distribution frequency in the control groups was consistent with Hardy-Weinberg equilibrium (HWE) for most studies, except for four studies \[[@R12], [@R19], [@R25], [@R49]\]. Each individual study scored more than 4 by Newcastle-Ottawa Scale (NOS), and was considered to be of high quality (Table [1](#T1){ref-type="table"}). The percentages of tt, Tt and TT genotype in case group and control group were 11.9%, 40.4%, 47.7% and 12.1%, 41.3%, 46.6%, respectively in overall population.

![Study flowchart for the process of selecting the final 36 studies](oncotarget-09-7136-g001){#F1}

###### Characteristics and quality assessment of the studies included in this meta-analysis

  -----------------------------------------------------------------------------------------------------------------------
  Author          Year   Country          Ethnicity       Genotyping method   Sample size\       Source of\   HWE   NOS
                                                                              (cases/controls)   Controls           
  --------------- ------ ---------------- --------------- ------------------- ------------------ ------------ ----- -----
  Andersson       2006   Sweden           Caucasian       PCR-RFLP            137/176            PB           Y     6

  Bai             2009   China            Asian           PCR-RFLP            122/130            HB           Y     6

  Blazer          2000   USA              Caucasian       PCR-RFLP            77/183             PB           Y     6

  Bodiwala        2004   UK               Caucasian       PCR-RFLP            368/243            BPH          N     6

  Chaimuangraj    2006   Thailand         Asian           PCR-RFLP            28/30/44           HB/BPH       Y     5

  Cicek           2006   USA              Mixed           PCR-RFLP            439/478            PB           Y     6

  Correa-Cerro    1999   Germany/France   Caucasian       PCR-RFLP            106/95             HB           Y     6

  Forrest         2005   UK               Caucasian       PCR-RFLP            262/444            HB           Y     6

  Furuya          1999   Japan            Asian           PCR-RFLP            66/60              HB           Y     5

  Gsur            2002   Austria          Caucasian       PCR-RFLP            190/190            BPH          Y     6

  Habuchi         2000   Japan            Asian           PCR-RFLP            222/128/209        HB/BPH       Y     6

  Hamasaki        2001   Japan            Asian           PCR-RFLP            115/133            HB           Y     6

  Hamasaki        2002   Japan            Asian           PCR-RFLP            110/90/83          HB/BPH       Y     6

  Holick          2007   USA              Caucasian       SNPlex              586/541            PB           Y     6

  Holt            2009   USA              Caucasian       SNPlex              697/697            PB           Y     6

  Hu              2014   China            Asian           TaqMan              108/242            PB           Y     6

  Huang           2004   China            Asian           PCR-RFLP            160/205            PB           Y     6

  Jingwi          2015   USA              African         TaqMan              306/251            PB           Y     6

  John            2005   USA              African/Asian   TaqMan              424/436            PB           Y     6

  Kambale         2017   India            Asian           PCR-RFLP            120/240            PB           N     5

  Kibel           1998   USA              Mixed           PCR-RFLP            41/41              PB           Y     5

  Luscombe        2001   UK               Caucasian       PCR-RFLP            209/154            BPH          Y     6

  Ma              1998   USA              Caucasian       PCR-RFLP            354/589            HB           Y     7

  Maistro         2004   Brazil           African         PCR-RFLP            165/200            HB           Y     6

  Medeiros        2002   Portugal         Caucasian       PCR-RFLP            162/206            PB           Y     6

  Oakley-Grivan   2004   USA              Mixed           PCR-RFLP            345/292            PB           Y     6

  Oh              2013   Korea            Asian           IGGGS               272/173            BPH          Y     6

  Onen            2008   Turkey           Caucasian       PCR-RFLP            133/157            PB           Y     6

  Onsory          2008   India            Asian           PCR-RFLP            100/100            PB           Y     6

  Rowland         2013   USA              Mixed           TaqMan              1617/1072          PB           Y     7

  Suzuki          2003   Japan            Asian           PCR-RFLP            81/105             HB           Y     5

  Tayeb           2003   UK               Caucasian       PCR-RFLP            21/379             BPH          Y     5

  Tayeb           2004   UK               Caucasian       PCR-RFLP            28/56              BPH          Y     5

  Taylor          1996   USA              Mixed           PCR-RFLP            108/170            BPH          Y     6

  Watanabe        1999   Japan            Asian           PCR-RFLP            100/202            BPH          N     5

  Yousaf          2014   Pakistani        Asian           PCR-RFLP            44/119             HB           N     5
  -----------------------------------------------------------------------------------------------------------------------

Abbreviations: HWE, Hardy-Weinberg equilibrium; PB, population-based; HB, hospital-based; BPH, Benign Prostate Hyperplasia; RFLP, restriction fragment length polymorphism; NOS, Newcastle-Ottawa Scale.

Pooled results {#s2_2}
--------------

As shown in Figure [2](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"}. Our results indicated that *Taq I* polymorphism marginally increase the PCa risk in the overall populations carrying TT genotype or T allele genotype (tt/Tt vs. TT: OR = 0.89, 95% CI = 0.80--1.00, *p* = 0.05; t vs. T allele: OR = 0.91, 95% CI = 0.84--0.99, *p* = 0.003), but not in other comparison models (tt vs. TT: OR = 0.86, 95% CI = 0.73−1.01, *p* = 0.069; Tt vs. TT: OR = 0.92, 95% CI = 0.81--1.10, *p* = 1.04; tt vs. TT/Tt: OR = 0.90, 95% CI = 0.76−1.06, *p* = 0.197) (Table [2](#T2){ref-type="table"}).

![Forest plots to estimate the association of *VDR Taq I* polymorphism with PCa in the overall analysis\
(**A**) Dominant model (tt/Tt vs. TT). (**B**) Allelic frequency model (t vs. T allele).](oncotarget-09-7136-g002){#F2}

###### Results of the association between *Taq I* polymorphism and PCa risk in the whole population

  Comparison    Studies   Overall effect        Heterogeneity   Publication bias                            
  ------------- --------- --------------------- --------------- ------------------ -------- ------- ------- -------
  tt vs TT      36        0.86 \[0.73--1.01\]   1.82            0.069              44.10%   0.004   0.382   0.363
  Tt vs TT      36        0.92 \[0.81--1.04\]   1.35            0.176              60%      0.000   0.955   0.891
  tt/Tt vs TT   36        0.89 \[0.80--1.00\]   1.96            0.05               56.20%   0.000   0.808   0.914
  tt vs TT/Tt   36        0.90 \[0.76--1.06\]   1.29            0.197              54.20%   0.000   0.318   0.496
  t vs T        36        0.91 \[0.84--0.99\]   2.18            0.03               56.90%   0.000   0.465   0.472

For the stratified analysis of different ethnicities, significantly increased risk was found in Asians in T allele genotype carriers (t vs. T: OR = 0.79, 95% CI = 0.68--0.91, *p* = 0.002) (Table [3](#T3){ref-type="table"} and Figure [2](#F2){ref-type="fig"}). However, when 15 studies performed in Caucasians and 3 studies in Africans were analyzed, no significant associations were found in any comparison models (Table [3](#T3){ref-type="table"}).

###### Results of the association between *Taq I* polymorphism and PCa risk in different ethnicities

  Comparison      Studies   Overall effect        Heterogeneity   Publication bias                         
  --------------- --------- --------------------- --------------- ------------------ ----- ------- ------- -------
  **Asian**                                                                                                
  tt vs TT        14        0.63 \[0.41--0.95\]   2.18            0.029              0%    0.504   0.312   0.981
  Tt vs TT        14        0.87 \[0.63--1.21\]   0.82            0.413              69%   0.000   0.033   0.022
  tt/Tt vs TT     14        0.80 \[0.63--1.03\]   1.71            0.087              53%   0.010   0.055   0.023
  tt vs TT/Tt     14        0.73 \[0.38--1.39\]   0.95            0.34               46%   0.046   0.243   0.414
  t vs T          14        0.78 \[0.67-0.90\]    3.14            0.002              7%    0.373   0.033   0.026
  **Caucasian**                                                                                            
  tt vs TT        15        0.99 \[0.86--1.14\]   0.08            0.935              56%   0.005   0.961   0.688
  Tt vs TT        15        0.99 \[0.85--1.16\]   0.08            0.933              50%   0.014   0.961   0.878
  tt/Tt vs TT     15        1.00 \[0.85--1.17\]   0.03            0.974              55%   0.05    0.961   0.762
  tt vs TT/Tt     15        1.01 \[0.81--1.26\]   0.08            0.938              62%   0.001   0.656   0.913
  t vs T          15        1.01 \[0.89--1.14\]   0.12            0.905              67%   0.000   0.729   0.884
  **African**                                                                                              
  tt vs TT        3         0.96 \[0.45--2.08\]   0.1             0.922              72%   0.027   0.602   0.603
  Tt vs TT        3         0.94 \[0.51--1.72\]   0.22            0.829              82%   0.004   0.602   0.632
  tt/Tt vs TT     3         0.94 \[0.50--1.78\]   0.18            0.855              85%   0.001   0.602   0.581
  tt vs TT/Tt     3         0.96 \[0.59--1.56\]   0.17            0.86               40%   0.189   0.602   0.515
  t vs T          3         0.96 \[0.61--1.52\]   0.18            0.86               85%   0.002   0.602   0.597

*Taq I* polymorphism could significantly increase PCa risk in the subgroup of population-based controls when patients carrying TT genotype or T allele genotype in all the genetic models (tt vs. TT: OR = 0.83, 95% CI = 0.73--0.94, *p* = 0.004; Tt vs. TT: OR = 0.83, 95% CI = 0.69--1.00, *p* = 0.049; tt/Tt vs. TT: OR = 0.82, 95% CI = 0.70--0.96, *p* = 0.016; tt vs. TT/Tt: OR = 0.88, 95% CI = 0.78--0.98, *p* = 0.023; t vs. T allele: OR = 0.89, 95% CI = 0.84--0.95, *p* = 0.000) (Table [4](#T4){ref-type="table"} and Figure [3](#F3){ref-type="fig"}). Meanwhile, results for the subgroups of hospital-based and BPH controls revealed no significantly increased risk (Table [4](#T4){ref-type="table"}).

###### Results of the association between *Taq I* polymorphism and PCa risk in different source of controls

  Comparison             Studies   Overall effect        Heterogeneity   Publication bias                         
  ---------------------- --------- --------------------- --------------- ------------------ ----- ------- ------- -------
  **Population-based**                                                                                            
  tt vs TT               16        0.83 \[0.73--0.94\]   2.98            0.003              2%    0.429   0.882   0.843
  Tt vs TT               16        0.83 \[0.69--1.00\]   1.97            0.049              73%   0.000   0.471   0.437
  tt/Tt vs TT            16        0.82 \[0.70--0.96\]   2.41            0.016              68%   0.000   0.719   0.419
  tt vs TT/Tt            16        0.88 \[0.78--0.98\]   2.28            0.023              27%   0.155   0.961   0.862
  t vs T                 16        0.89 \[0.84--0.95\]   3.89            0.000              39%   0.057   0.418   0.297
  **Hospital-based**                                                                                              
  tt vs TT               12        0.90 \[0.51--1.59\]   0.37            0.710              70%   0.000   0.815   0.481
  Tt vs TT               12        1.02 \[0.81--1.30\]   0.19            0.851              50%   0.025   0.411   0.406
  tt/Tt vs TT            12        0.99 \[0.78--1.27\]   0.07            0.946              57%   0.008   0.681   0.752
  tt vs TT/Tt            12        0.89 \[0.51--1.54\]   0.42            0.675              72%   0.000   0.484   0.390
  t vs T                 12        0.97 \[0.76--1.25\]   0.21            0.832              77%   0.000   0.681   0.767
  **BPH**                                                                                                         
  tt vs TT               11        0.90 \[0.68--1.19\]   0.75            0.451              20%   0.267   0.677   0.476
  Tt vs TT               11        1.01 \[0.85--1.20\]   0.11            0.911              25%   0.208   0.938   0.715
  tt/Tt vs TT            11        0.98 \[0.83--1.16\]   0.22            0.823              17%   0.282   0.586   0.586
  tt vs TT/Tt            11        0.85 \[0.66--1.10\]   1.23            0.217              43%   0.083   0.677   0.585
  t vs T                 11        0.95 \[0.85--1.08\]   0.76            0.447              24%   0.219   0.586   0.501

![Forest plots to estimate the association of *VDR Taq I* polymorphism with PCa in Asians\
(**A**) Homozygote model (tt vs. TT). (**B**) Allelic frequency model (t vs. T allele).](oncotarget-09-7136-g003){#F3}

Studies were stratified into TaqMan, PCR-RFLP, and SNPlex groups by genotyping methods. No significant association was found in almost subgroups, except TaqMan group in tt vs. TT/Tt comparison (Table [5](#T5){ref-type="table"}). The pooled outcome indicated that the genotyping methods included in these studies are both available and did not alter the outcomes.

###### Results of the association between *Taq I* polymorphism and PCa risk in different genotyping method

  Comparison     Studies   Overall effect        Heterogeneity   Publication bias                         
  -------------- --------- --------------------- --------------- ------------------ ----- ------- ------- -------
  **PCR-RFLP**                                                                                            
  tt vs TT       29        0.88 \[0.71--1.01\]   1.13            0.258              46%   0.006   0.393   0.283
  Tt vs TT       29        0.94 \[0.80--1.10\]   0.77            0.441              62%   0.000   0.970   0.702
  tt/Tt vs TT    29        0.91 \[0.79--1.05\]   1.31            0.19               57%   0.000   0.851   0.995
  tt vs TT/Tt    29        0.90 \[0.71--1.13\]   0.93            0.35               58%   0.000   0.307   0.277
  t vs T         29        0.92 \[0.82--1.03\]   1.51            0.13               59%   0.000   0.476   0.424
  **TaqMan**                                                                                              
  tt vs TT       4         0.71 \[0.53--0.94\]   2.38            0.017              32%   0.219   1.000   0.794
  Tt vs TT       4         0.85 \[0.69--1.05\]   1.50            0.134              44%   0.147   0.174   0.691
  tt/Tt vs TT    4         0.82 \[0.65--1.02\]   1.79            0.074              53%   0.093   0.497   0.812
  tt vs TT/Tt    4         0.77 \[0.64--0.93\]   2.68            0.007              3%    0.378   1.000   0.618
  t vs T         4         0.83 \[0.71--0.97\]   2.36            0.018              49%   0.117   1.000   0.995
  **SNPlex**                                                                                              
  tt vs TT       3         0.95 \[0.75--1.20\]   0.43            0.669              0%    0.322   0.317   \-
  Tt vs TT       3         0.91 \[0.60--1.39\]   0.43            0.664              78%   0.010   0.602   0.999
  tt/Tt vs TT    3         0.92 \[0.64--1.33\]   0.45            0.656              74%   0.022   0.602   0.997
  tt vs TT/Tt    3         1.01 \[0.81--1.25\]   0.05            0.961              0%    0.783   0.317   \-
  t vs T         3         0.96 \[0.82--1.23\]   0.52            0.603              37%   0.203   0.602   0.987

As shown in Figure [4](#F4){ref-type="fig"} and Table [6](#T6){ref-type="table"}, we also performed a stratified analysis based on the clinical stages by Gleason Score to describe the relationship in more detail. The pooled results from 9 studies for advanced tumor group and 8 studies for localized tumor group did not reveal any association of *Taq I* polymorphism with the PCa risk in various genetic models. When 4 studies deviated from HWE in the controls were excluded, similar results were obtained (The results were not given).

![Forest plots to estimate the association of *VDR Taq I* polymorphism with PCa in the subgroup of population-Based controls\
(**A**) Homozygote model (tt vs. TT). (**B**) Allelic frequency model (t vs. T allele).](oncotarget-09-7136-g004){#F4}

###### Results of the association between *Taq I* polymorphism and PCa risk in different tumor stage

  Comparison      Studies   Overall effect        Heterogeneity   Publication bias                         
  --------------- --------- --------------------- --------------- ------------------ ----- ------- ------- -------
  **Advanced**                                                                                             
  tt vs TT        9         0.87 \[0.66--1.14\]   1.02            0.307              23%   0.243   0.621   0.763
  Tt vs TT        9         0.85 \[0.65--1.11\]   1.18            0.237              53%   0.030   0.404   0.357
  tt/Tt vs TT     9         0.84 \[0.64--1.10\]   1.28            0.200              59%   0.012   0.532   0.347
  tt vs TT/Tt     9         0.92 \[0.69--1.22\]   0.59            0.552              34%   0.155   0.621   0.686
  t vs T          9         0.88 \[0.70--1.10\]   1.14            0.252              66%   0.003   0.211   0.301
  **Localized**                                                                                            
  tt vs TT        8         0.63 \[0.27--1.45\]   1.10            0.273              85%   0.000   0.453   0.966
  Tt vs TT        8         0.90 \[0.66--1.24\]   0.63            0.531              61%   0.013   0.458   0.901
  tt/Tt vs TT     8         0.84 \[0.56--1.27\]   0.83            0.406              79%   0.000   0.458   0.933
  tt vs TT/Tt     8         0.66 \[0.35--1.22\]   1.33            0.182              76%   0.000   0.652   0.891
  tvs T           8         0.84 \[0.69--1.01\]   0.95            0.344              86%   0.000   0.621   0.903

Heterogeneity {#s2_3}
-------------

Significant between-study heterogeneity was detected in the overall analysis for all the comparison models (tt vs. TT: *p* = 0.004, I^2^ = 44%) Tt vs. TT: *p* = 0.000, I^2^ = 60%; tt/Tt vs. TT: *p* = 0.000, I^2^ = 56%; t vs. TT/Tt: *p* = 0.000, I^2^ = 54%; and t vs. T allele: *p* = 0.000, I^2^ = 57%) (Table [2](#T2){ref-type="table"}). Therefore, random-effects estimates would be more suitable for data analysis. In the subgroup analyses of ethnicity, no heterogeneity was detected in homozygosis genetic model (*p* = 0.504, I^2^ = 0%) or allele-frequency model (*p* = 0.373, I^2^ = 7%) (Table [3](#T3){ref-type="table"}). Similarly, subgroup analysis of population-based controls reported no heterogeneity in homozygosis model, recessive model or allele-frequency model (Table [4](#T4){ref-type="table"}). Fix-effect model was applied in these comparison models.

Publication bias and sensitivity analysis {#s2_4}
-----------------------------------------

As shown in Figure [5](#F5){ref-type="fig"}, funnel plots did not reveal any obvious asymmetry. Moreover, the Egger\'s test also showed that there was no publication bias in the overall analysis (Table [2](#T2){ref-type="table"}) and almost the subgroup analyses (Table [3](#T3){ref-type="table"}-[6](#T6){ref-type="table"}). Sensitivity analyses suggested that the pooled results had not changed significantly by omitting each individual study from all the analyses (Figure [6](#F6){ref-type="fig"}).

![Begg\'s funnel plots to examine publication bias for reported comparisons of *VDR* gene *Taq I* polymorphism for the homozygote in (A) Subgroup of Asians\
(**B**) Subgroup of Population-Based controls.](oncotarget-09-7136-g005){#F5}

![Sensitivity analysis of the comparison in Allelic frequency model (t vs. T allele) in Asians](oncotarget-09-7136-g006){#F6}

DISCUSSION {#s3}
==========

In recent years, polymorphism of *VDR* gene has drawn great attention, because more and more studies have shown that the mutations of *VDR* gene were related to the PCa risk \[[@R14]--[@R19]\]. However, these results have been disputable \[[@R20]--[@R22]\]. Previous meta-analyses were reported by Yin et al. in 2009, Fei et al. in 2016 and Liu et al. in 2017 \[[@R10], [@R23], [@R24]\], in which the number of included studies was 23, 27 and 8, respectively. However, some new data was reported, which is not consistent with the results of the former three studies \[[@R17], [@R25]--[@R27]\]. 8,423 cases and 8,867 controls were included in our analysis from 36 independent studies. The cases included were much more than the previous meta-analyses. Therefore, our results might be more convincing and stringent.

Our meta-analysis showed that *Taq I* polymorphism might increase the PCa risk in overall population in recessive genetic model and allele-frequency genetic model. It is not consistent with the results of previous report by Liu et al. \[[@R10]\]. But for the stratified analysis of ethnicity, significant increased risk was found to be associated with *Taq I* polymorphism in Asians, which is consistent with the results of the report of Fei et al \[[@R24]\]. Ethnicity is an important biological factor for the decline of VDR function \[[@R50]\]. The difference in outcome among ethnicities might result from racial backgrounds and geographic discrepancies \[[@R51]\]. In addition, different dietary patterns could also contribute to the difference \[[@R52]\]. Our results suggested that the *Taq I* variation might be one of the valuable biomarkers for predicting the susceptibility of PCa. Further studies of Caucasian and African are required.

For the subgroup analysis by the source of controls, increased risk of PCa was found to be associated with *Taq I* polymorphism in population-based controls in all the comparisons. Possibly some sick population were included in the groups of HBP or hospital-based controls, these groups were special and could not represent all the population \[[@R53]\]. Therefore, the results of these groups might be lack of credibility. Our results revealed some discrepancies between the genotyping methods. It suggested that *Taq I* polymorphism in the subgroup of TaqMan, *Taq I* was associated with PCa risk, which may be the cause of heterogeneity. According to a report in 2004, clinical tumor stage of PCa would be accelerated by *VDR* gene polymorphism \[[@R54]\]. Hence, we performed a subgroup analysis by clinical stage. Our results indicated no association between *Taq I* polymorphism and susceptibility of PCa, which were different from the previous meta-analyses \[[@R24]\].

Although the between-study heterogeneity was detected, sensitivity analysis did not reveal any significant change in our results by omitting the studies contribute to the heterogeneity. It suggested that our results were credible and statistically robust.

Some limitations should be acknowledged. First, several studies with too little number of patients were included in our analysis, they may introduce potential bias. Second, our results were based on unadjusted parameters, a more accurate analysis are needed, in which some related parameters should be included to adjust the outcome, including age, diet, and other important lifestyle factors.

In conclusion, our meta-analysis might be the largest meta-analysis to estimate the association of *VDR* gene *Taq I* polymorphism with the risk of PCa. Marginally increase of PCa risk was found to be related with *Taq I* polymorphism in overall population, especially in Asians and in population-based controls subgroup. In the future, large and well-designed researches are required to demonstrate the increased effect of *Taq I* polymorphism on PCa risk.

MATERIALS AND METHODS {#s4}
=====================

Literature and search strategy {#s4_1}
------------------------------

The PubMed, Embase, and Chinese National Knowledge Infrastructure (CNKI) database searches were carried out for all the eligible papers. The following search terms were included: "*VDR*/vitamin D receptor", "prostate cancer/tumor/carcinoma" and "polymorphism/mutation/variant". The literature search was updated to August, 2017. In addition, manually searching for the additional studies was conducted according to the references of the original and review reports.

Study selection {#s4_2}
---------------

Retrieved studies were deemed eligible provided that they met all of the following criteria: (a) studies on human beings; (b) in a case-control or nested case-control design; (c) investigated the relationship of *Taq I* polymorphism with PCa risk; (d) distribution of genotype frequency for cases and controls could be obtained or calculated; (e) and received more than 4 points in the NOS, which was considered to be high quality; (f) the difference of baseline characters and clinical information was not significant between PCa patients and controls.

Data extraction {#s4_3}
---------------

The studies meeting the inclusion criteria were read carefully by two investigators independently (Yansheng Zhao and Xiaofeng Liu). We collected the following information: author, year, country, ethnicity, genotyping methods, source of controls, sample size, and genotype and allele frequencies. The subjects were divided into different subgroups: Asians, Africans and Caucasians for ethnicity; hospital-based, population-based, and Benign Prostate Hyperplasia (BPH) for the source of controls; TaqMan, PCR-RFLP and SNPlex for genotyping method. The clinical stages were categorized as localized group (Gleason \< 7) and advanced group (Gleason ≥ 7). In order to reach consensus on all of the items, any disagreement was resolved by a third reviewer (Lei Wang).

Statistical analysis {#s4_4}
--------------------

A χ^2^-test based on the Q statistic was conducted to evaluate the heterogeneity. The between-study heterogeneity was considered to be significant when I^2^ \> 50% and *p* \< 0.05, and the random effects model was used to combine values from studies \[[@R55]\]. Otherwise, for homogeneous studies, the fixed effects model was chosen.

The pooled odds ratios (ORs) together with its 95% confidence intervals (95% CIs) were calculated to evaluate the strength of the association. The statistical significance of ORs was determined with Z-test. To get a more reasonable result, five genetic models were adopted in our analysis: homozygote model (tt vs. TT), heterozygous model (Tt vs. TT), dominant model (tt vs. TT/Tt), recessive model (tt/Tt vs. TT) and allele genetic model (t vs. T).

To assess the potential publication bias, Begg\'s Funnel plot was generated based on the analysis result and database size. The more asymmetry the funnel plot looked, the more publication bias was introduced. Meanwhile, Egger\'s test was also performed for further investigation. For the Egger\'s test, the significance level was set as *p* value \< 0.05. Moreover, HWE of controls was recalculated with the goodness-of-fit χ^2^-test, *P* values of \> 0.05 was considered as significant equilibrium.

For each outcome, we also performed subgroup analyses according to ethnicity, source of controls, genotyping method and clinic stages. Sensitivity analysis was performed to assess the stability of pooled results.

All analyses were performed using STATA package version 12.0 (Stata Corp, College Station, TX, USA). Two-sided *P* values of \< 0.05 was considered to be statistically significant.

Conceived and designed the experiments: Shaosan Kang and Yansheng Zhao. Extracted data: Yansheng Zhao, Xiaofeng Liu and Lei Wang. Performed the data analysis: Jian Liu, Xi Chen and Zhijie Shi. Wrote the paper: Weixing Gao and Fenghong Cao.

**CONFLICTS OF INTEREST**

The authors report no conflicts of interest.

**GRANT SUPPORT**

None.
